UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
- Status
- COMPLETED
- Phase
- PHASE2
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
- Status
- TERMINATED
- Phase
- PHASE2
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
- Status
- COMPLETED
- Phase
- PHASE2
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
- Status
- COMPLETED
- Phase
- PHASE1
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2